Join

Compare · AUTL vs MRNA

AUTL vs MRNA

Side-by-side comparison of Autolus Therapeutics plc (AUTL) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AUTL and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • MRNA is the larger of the two at $26.76B, about 69.3x AUTL ($385.9M).
  • Over the past year, AUTL is down 41.5% and MRNA is up 113.5% - MRNA leads by 155.1 points.
  • AUTL has been more active in the news (12 items in the past 4 weeks vs 9 for MRNA).
  • MRNA has more recent analyst coverage (25 ratings vs 6 for AUTL).
PerformanceAUTL-41.53%MRNA+113.52%
2025-07-15+0.00%2026-07-14
MetricAUTLMRNA
Company
Autolus Therapeutics plc
Moderna Inc.
Price
$1.45-2.03%
$67.43+0.66%
Market cap
$385.9M
$26.76B
1M return
-7.64%
+35.80%
1Y return
-41.53%
+113.52%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2018
2018
News (4w)
12
9
Recent ratings
6
25
AUTL

Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

MRNA

Moderna Inc.

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest AUTL

Latest MRNA